Document is current
Any future updates will be listed below
-
Authors
Chipps, Bradley E
Albers, Frank C
Reilly, Laurence
Johnsson, Eva
Cappelletti, Christy
Papi, Alberto
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03769090 at ClinicalTrials.govnct02105012 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study
https://doi.org/10.1136/bmjresp-2021-001077
Efficacy and safety of as-needed albuterol–budesonide versus albuterol in patients with asthma aged 12 to <18 years: design of the randomised, double-blind, parallel-group phase IIIb ACADIA trial
https://doi.org/10.1136/bmjresp-2025-003843
nct03847896 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study
https://doi.org/10.1136/bmjresp-2021-001077
Documents that mention this clinical trial
Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study
https://doi.org/10.1136/bmjresp-2021-001077
Efficacy and safety of as-needed albuterol–budesonide versus albuterol in patients with asthma aged 12 to <18 years: design of the randomised, double-blind, parallel-group phase IIIb ACADIA trial
https://doi.org/10.1136/bmjresp-2025-003843
-
Funding
Funding for this research was provided by:
Avillion (Not Applicable)
- License Information
